Organon (OGN) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 04/13/26
These Stocks Are Today's Movers: Nvidia, Intel, Lumentum, Coherent, Organon, and More.Barrons • 04/10/26
Organon (OGN) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research • 03/27/26
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of AgeBusiness Wire • 03/27/26
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?The Motley Fool • 03/20/26
Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to KnowZacks Investment Research • 03/18/26
KDventures announces that Organon has discontinued the development of the previous portfolio company Forendos' drug candidate for PCOSGlobeNewsWire • 03/03/26
OGN's VTAMA Cream Shows Sleep Benefits in Pediatric Atopic DermatitisZacks Investment Research • 03/02/26
New Analysis of Organon's VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic DermatitisBusiness Wire • 02/27/26
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals' Hormone-Free Intrauterine DeviceBusiness Wire • 02/23/26
Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/12/26
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025Business Wire • 02/12/26
Organon (OGN) Stock Falls Amid Market Uptick: What Investors Need to KnowZacks Investment Research • 02/02/26
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026Business Wire • 01/29/26